Tradition Wealth Management LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 16.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 717 shares of the company’s stock after buying an additional 100 shares during the period. Tradition Wealth Management LLC’s holdings in Zoetis were worth $119,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of ZTS. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in shares of Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares during the last quarter. Worth Asset Management LLC bought a new position in Zoetis in the 1st quarter worth about $26,000. IAG Wealth Partners LLC bought a new position in Zoetis in the 4th quarter worth about $29,000. HHM Wealth Advisors LLC grew its position in Zoetis by 1,160.0% in the 1st quarter. HHM Wealth Advisors LLC now owns 189 shares of the company’s stock worth $31,000 after purchasing an additional 174 shares during the last quarter. Finally, Elequin Securities LLC bought a new position in Zoetis in the 4th quarter worth about $32,000. Institutional investors own 89.47% of the company’s stock.
Analysts Set New Price Targets
Several research firms have commented on ZTS. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Monday, August 14th. Stifel Nicolaus increased their price objective on shares of Zoetis from $195.00 to $205.00 and gave the company a “buy” rating in a report on Monday. StockNews.com upgraded shares of Zoetis from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Finally, The Goldman Sachs Group increased their price objective on shares of Zoetis from $204.00 to $213.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $224.43.
Insider Transactions at Zoetis
In other news, EVP Robert J. Polzer sold 1,179 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $189.94, for a total transaction of $223,939.26. Following the transaction, the executive vice president now owns 2,353 shares in the company, valued at approximately $446,928.82. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Zoetis news, CEO Kristin C. Peck sold 13,000 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total value of $2,339,610.00. Following the completion of the sale, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at approximately $10,230,034.71. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Robert J. Polzer sold 1,179 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $189.94, for a total transaction of $223,939.26. Following the completion of the sale, the executive vice president now directly owns 2,353 shares of the company’s stock, valued at $446,928.82. The disclosure for this sale can be found here. 0.15% of the stock is currently owned by company insiders.
Zoetis Stock Down 0.0 %
Shares of NYSE:ZTS opened at $192.70 on Thursday. The company has a debt-to-equity ratio of 1.42, a quick ratio of 1.97 and a current ratio of 3.50. The company has a market cap of $88.70 billion, a PE ratio of 40.48, a price-to-earnings-growth ratio of 3.01 and a beta of 0.78. Zoetis Inc. has a 52 week low of $124.15 and a 52 week high of $194.99. The firm has a 50 day simple moving average of $179.46 and a 200 day simple moving average of $173.75.
Zoetis (NYSE:ZTS – Get Free Report) last released its earnings results on Tuesday, August 8th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.10. Zoetis had a net margin of 26.92% and a return on equity of 52.02%. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.16 billion. During the same quarter in the prior year, the firm earned $1.20 EPS. The company’s revenue was up 3.8% compared to the same quarter last year. As a group, research analysts expect that Zoetis Inc. will post 5.42 earnings per share for the current year.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
- Five stocks we like better than Zoetis
- What Investors Need to Know to Beat the Market
- 3 Online Retailers To Revamp Your Shopping List With
- How to Buy Metaverse Stock Step by Step
- 3 Bitcoin Stocks To Watch Following Grayscale’s Legal Victory
- How Investors Can Identify and Successfully Trade Gap-Up Stocks
- The Top 5 High Yield Blue Chip Dividend-Paying Tech Stocks
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.